Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …

Abstract Disease Overview Diffuse large B‐cell lymphoma (DLBCL) is the most common
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …

Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …

Background Patients with relapsed or refractory large B-cell lymphoma after first-line
treatment who are not intended for haematopoietic stem-cell transplantation (HSCT) have …

Great heterogeneity in survival exists for patients newly diagnosed with diffuse large B-cell
lymphoma (DLBCL). Three scoring systems incorporating simple clinical parameters (age …

Purpose To update the 2006 American Society of Clinical Oncology guideline on the use of
hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical …

Diffuse large B-cell lymphoma (DLBCL) is nowadays a curable disease with the frontline
treatment R-CHOP, but 30–40% of patients are still unresponsive or relapse thereafter. In …

Purpose Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisone) chemotherapy is the standard of care in previously untreated diffuse large B …

Background Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified
using gene-expression analysis to determine their cell of origin, corresponding to germinal …

Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …